Amir Mohsenin

Amir Mohsenin practices at Mann Eye Center, PA in Humble, Texas.

Amir Mohsenin's NPI, 1053638312, was assigned on April 27, 2010. Amir Mohsenin graduated from McGovern Medical School in 2009. Amir Mohsenin's Texas license number on file is Q5041.

Amir Mohsenin's primary practice is Mann Eye Center, PA, at 18850 S Memorial Blvd, Humble, TX 77338 in Harris County. The practice phone is (713) 275-2456.

Amir Mohsenin's primary practice is Mann Eye Center, PA in Humble, Texas. Dmand AI also links Amir Mohsenin to 2 group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Amir Mohsenin practices, 2 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Amir Mohsenin's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Amir Mohsenin is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Amir Mohsenin's licenses on file in 2 states: Texas and Florida.

Dmand AI lists age-related macular degeneration, cataract, dry eye, glaucoma, hypertensive retinopathy, laser destruction of retinal or choroid lesions, retinal detachment and retinal occlusion among the conditions Amir Mohsenin treats.

CMS data shows 17,742 Medicare services from Amir Mohsenin across 11 procedure codes in 2024, for 473 Medicare patients. Medicare paid $1,203,520 for them. Every service was in an office.

CMS counts 473 Medicare patients who saw Amir Mohsenin in 2024. The largest group is 65 to 74, with 217 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 5% are also on Medicaid. Their average risk score is 1.46, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Amir Mohsenin's median patient age at 70, with 57% women.

In 2024, Amir Mohsenin wrote 308 Medicare Part D claims for 73 patients. 46% of them were for generic drugs. CMS names the drug for 265 of them, across 6 drugs with 11 or more claims each, at $33,842 in total drug cost. In 2023, CMS named 216 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 87 out of 100 for Amir Mohsenin for performance year 2024, reported as part of a group. Amir Mohsenin accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 15 papers to Amir Mohsenin, published from 2007 to 2013. The most frequent topics are Lung, Mice, Knockout and Pneumonia. Amir Mohsenin has published most often in Clin Ophthalmol. Amir Mohsenin's most frequent co-authors are Joseph A. Madri, MD, Ron Afshari Adelman, MD and Sander R. Dubovy, MD.

CMS Open Payments shows 206 general payments to Amir Mohsenin from 22 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 88% of the total. Sun Pharmaceutical Industries Inc. paid the most, $1,572.

Dmand AI lists 1 award for Amir Mohsenin, most recently Marvin Sears Award for Clinical Excellence in 2012.

Amir Mohsenin graduated from McGovern Medical School in 2009.

Amir Mohsenin is in network with 21 carriers, including Aetna, Blue Cross Blue Shield of Michigan and HCSC. HMO plans come from the most carriers, 13. Check the plan with the practice before a visit.